A diagnosis of septic shock was once a near death sentence. At best, survivors suffered a substantially reduced quality of life.
Perelman School of Medicine
Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.
Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School,
By Madeleine Stone @themadstone
A $10 million gift to the University of Pennsylvania to name the Paul F. Harron, Jr.
Penn Medicine's Basser Research Center for BRCA Announces $6.9 Million in New Grants to Further BRCA1 and BRCA2 Mutation Research
The University of Pennsylvania’s Basser Research Center for BRCA has announced $6.9 million to resea
A new form of gene therapy for boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a life-threatening condition also known as “bubble boy” disease, appears to be both effective and safe, according to an international clinical trial with sites in Boston, Cincinnati, Los Angeles, London, a
A first-of-its-kind set of questions included in the Internal Medicine In-Training Examination (IM-ITE) illustrates the need to better evaluate resident proficiency in high-value care (HVC), according to a new study published in Annals of
Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School says, “We do have to step up training.